Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billion. On the basis of U.S. generally ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Zydus Lifesciences reported 29.62% jump in consolidated net profit of Rs 1,023.5 crore inQ3 FY25 compared with Rs 789.6 crore in Q3 FY24.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

Psychedelic therapy is set to launch in Colorado this spring, with the state considering licenses for healing centers, ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Pharma major Dr. Reddy’s Laboratories Ltd. on Thursday announced its consolidated financial results for the quarter and nine ...

A bill introduced this legislative session aims to prohibit the sale of certain marijuana products to customers aged 21 to 25 ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.